CoChat

Disruption of IRE1α through its kinase domain attenuates multiple myeloma

Open access
Harnoss, Jonathan M., Le Thomas, Adrien, Shemorry, Anna, Marsters, Scot A., Lawrence, David A., Lu, Min, Chen, Yung-Chia Ariel, Qing, Jing, Totpal, Klara, Kan, David, Segal, Ehud, Merchant, Mark, Reichelt, Mike, Ackerly Wallweber, Heidi, Wang, Weiru, Clark, Kevin, Kaufman, Susan, Beresini, Maureen H., Laing, Steven T., Sandoval, Wendy, Lorenzo, Maria, Wu, Jiansheng, Ly, Justin, De Bruyn, Tom, Heidersbach, Amy, Haley, Benjamin, Gogineni, Alvin, Weimer, Robby M., Lee, Dong, Braun, Marie-Gabrielle, Rudolph, Joachim, VanWyngarden, Michael J., Sherbenou, Daniel W., Gomez-Bougie, Patricia, Amiot, Martine, Acosta-Alvear, Diego, Walter, Peter, Ashkenazi, Avi · 2019 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Significance: Multiple myeloma (MM) is a lethal malignancy arising from plasma cells. MM cells experience endoplasmic reticulum (ER) stress due to immunoglobulin hyperproduction. The ER-resident sensor IRE1α mitigates ER stress by expanding protein-folding and secretion capacity, while supporting proteasomal degradation of ER misfolded proteins. IRE1α elaborates these functions by deploying a cytoplasmic kinase–RNase module to activate the transcription factor XBP1s. Although IRE1α has been implicated in MM, its validity as a potential therapeutic target—particularly as a kinase—has been unclear. Using genetic and pharmacologic disruption, we demonstrate that the IRE1α–XBP1s pathway is critical for MM tumor growth. We further show that the kinase domain of IRE1α is an effective and safe potential small-molecule target for MM therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1906999116

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Expression of IRE1α in MM cell lines and effect of its depletion on spheroid 3D growth. (A) Twelve human MM cell lines were analyzed by immunoblot (IB) for protein levels of IRE1α and XBP1s. (B–F) KMS-11, OPM-2, and RPMI-8226 MM cells were stably transfected with a plasmid encoding doxycycline (Dox)-inducible shRNAs against IRE1α together with a plasmid encoding mCherry. Cells were incubated in the absence or presence of Dox (0.5 μg/mL) for 3 d, seeded on ultralow adhesion (ULA) plates, centrifuged to form single spheroids, and analyzed by IB for indicated proteins (B) or for growth based on mCherry fluorescence using an Incucyte instrument. (C–E, Lower) Representative images of indicated MM cells grown as single spheroids in ULA plates. (Scale bars, 800 μm.)
Fig. 1. Expression of IRE1α in MM cell lines and effect of its depletion on spheroid 3D growth. (A) Twelve human MM cell lines were analyzed by immunoblot (IB) for protein levels of IRE1α and XBP1s. (B–F) KMS-11, OPM-2, and RPMI-8226 MM cells were stably transfected with a plasmid encoding doxycycline (Dox)-inducible shRNAs against IRE1α together with a plasmid encoding mCherry. Cells were incubated in the absence or presence of Dox (0.5 μg/mL) for 3 d, seeded on ultralow adhesion (ULA) plates, centrifuged to form single spheroids, and analyzed by IB for indicated proteins (B) or for growth based on mCherry fluorescence using an Incucyte instrument. (C–E, Lower) Representative images of indicated MM cells grown as single spheroids in ULA plates. (Scale bars, 800 μm.)CC BY-NC-ND · PubMed Central
Fig. 2. Genetic disruption of IRE1α or XBP1 attenuates growth of s.c. human MM xenografts in mice. (A) IRE1α was disrupted by CRISPR/Cas9 in KMS-11 cells. Parental or corresponding knockout (KO) clones were injected s.c. (SC) into C.B-17 SCID mice and monitored for tumor growth. (B) KMS-11 IRE1α KO Cl. 2.3 cells were stably transfected with expression plasmids encoding wild-type (WT) IRE1α (WT RIRE1α) or kinase-dead (KD) D688N mutant IRE1α (KD RIRE1α), injected SC into mice and monitored for tumor growth. (C) XBP1 was disrupted by CRISPR/Cas9 in KMS-11 cells. Parental or corresponding KO clones were injected SC and monitored for tumor growth (mean tumor volume ± SEM). (D and E) KMS-11 (D) or RPMI-8226 (E) cells with Dox-inducible shRNAs against IRE1α were inoculated SC and allowed to establish tumors. Mice were then randomized into treatment groups (n = 10 mice per group in D, n = 8 or 9 mice per group in E): vehicle (sucrose), Dox in drinking water (D and E), bortezomib (BTZ), alone or with Dox (D), or lenalidomide (LEN), alone or with Dox (E), and tumor growth was monitored. Individual mouse data are in SI Appendix, Fig. S2 G and H. (F) KMS-11 parental, IRE1α, or XBP1s KO cells were treated with DMSO or Tg (100 nM) for 6 h and analyzed by RNAseq. Fold change in mRNA is shown for the indicated ERAD components. (G) Human free IgG κ light chains were quantified in KMS11 parental or IRE1α KO Cl. 2.3 cell supernatants by ELISA 9 h after seeding. Fold change in secretion for equal cell numbers is shown. (H) RPMI-8226 cells with Dox-inducible shRNAs against IRE1α were incubated with Dox (0 or 1 μg/mL) for 3 d and analyzed by RT-qPCR. Fold change in mRNA is shown for the indicated ERAD components. (I) RPMI-8226 cells with Dox-inducible shRNAs against NTC or IRE1α were incubated with Dox (0 or 1 μg/mL) for 3 d, equal number of cells seeded, and human free IgG λ light chains quantified in cell supernatants by ELISA 9 h later. (J) Mice bearing SC tumor xenografts of RPMI-8226 cells with Dox-inducible shRNAs against IRE1α were treated with Dox in drinking water, and sera were collected and analyzed by luminex for fold change in the concentrations of indicated cytokines and chemokines. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. NS, not significant.
Fig. 2. Genetic disruption of IRE1α or XBP1 attenuates growth of s.c. human MM xenografts in mice. (A) IRE1α was disrupted by CRISPR/Cas9 in KMS-11 cells. Parental or corresponding knockout (KO) clones were injected s.c. (SC) into C.B-17 SCID mice and monitored for tumor growth. (B) KMS-11 IRE1α KO Cl. 2.3 cells were stably transfected with expression plasmids encoding wild-type (WT) IRE1α (WT RIRE1α) or kinase-dead (KD) D688N mutant IRE1α (KD RIRE1α), injected SC into mice and monitored for tumor growth. (C) XBP1 was disrupted by CRISPR/Cas9 in KMS-11 cells. Parental or corresponding KO clones were injected SC and monitored for tumor growth (mean tumor volume ± SEM). (D and E) KMS-11 (D) or RPMI-8226 (E) cells with Dox-inducible shRNAs against IRE1α were inoculated SC and allowed to establish tumors. Mice were then randomized into treatment groups (n = 10 mice per group in D, n = 8 or 9 mice per group in E): vehicle (sucrose), Dox in drinking water (D and E), bortezomib (BTZ), alone or with Dox (D), or lenalidomide (LEN), alone or with Dox (E), and tumor growth was monitored. Individual mouse data are in SI Appendix, Fig. S2 G and H. (F) KMS-11 parental, IRE1α, or XBP1s KO cells were treated with DMSO or Tg (100 nM) for 6 h and analyzed by RNAseq. Fold change in mRNA is shown for the indicated ERAD components. (G) Human free IgG κ light chains were quantified in KMS11 parental or IRE1α KO Cl. 2.3 cell supernatants by ELISA 9 h after seeding. Fold change in secretion for equal cell numbers is shown. (H) RPMI-8226 cells with Dox-inducible shRNAs against IRE1α were incubated with Dox (0 or 1 μg/mL) for 3 d and analyzed by RT-qPCR. Fold change in mRNA is shown for the indicated ERAD components. (I) RPMI-8226 cells with Dox-inducible shRNAs against NTC or IRE1α were incubated with Dox (0 or 1 μg/mL) for 3 d, equal number of cells seeded, and human free IgG λ light chains quantified in cell supernatants by ELISA 9 h later. (J) Mice bearing SC tumor xenografts of RPMI-8226 cells with Dox-inducible shRNAs against IRE1α were treated with Dox in drinking water, and sera were collected and analyzed by luminex for fold change in the concentrations of indicated cytokines and chemokines. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. NS, not significant.CC BY-NC-ND · PubMed Central
Fig. 3. Importance of IRE1α kinase in RNase activation in growth of MM cell lines in 3D versus 2D. (A) KMS-11 IRE1α knockout (KO) cells (Cl. 2.3) were transiently transfected with expression plasmids encoding wild-type IRE1α (WT RIRE1α), a “kinase-dead” D688N mutant of IRE1α (KD RIRE1α), or an “autophosphorylation-deficient” S724A, S726A, S729A triple mutant of IRE1α (PD RIRE1α). Cells were then incubated in the absence or presence of thapsigargin (Tg, 100 nM) for 3 h and analyzed either by IB for levels of the indicated proteins or by RT-qPCR for mRNA levels of XBP1s. (B) Chemical structures of compounds 18 and 16 (35) and KIRA6 (42). (C) A close-up view of the crystal structure of 18 in complex with the kinase-RNase portion of IRE1α. The protein is rendered in ribbons with key residues in the ligand-binding pocket shown as sticks. Water molecules near the ligand are shown in red spheres. Black dashed lines indicate hydrogen bonding interactions. (D) Comparison between the cocrystal structures of 18 (colored in wheat and orange versus 16 (PDB ID code 4U6R, colored cyan and blue) bound to IRE1α. The C-terminal end of the αC-helix displays significant conformational changes between the two structures. (E) KMS-11, OPM-2, and RPMI-8226 cells were seeded on standard tissue culture plates (2D) or ULA plates followed by centrifugation to form single spheroids (3D). After 96 h, cells were lysed and analyzed by IB for indicated proteins. (F–H) Cells were seeded either in the 2D or 3D setting, treated for 150 h with vehicle (DMSO) or compound 18 at the indicated concentrations, and analyzed for cell growth by cell confluence using an Incucyte instrument (F) or cell viability using CellTiter-Glo 3D (G and H). **P ≤ 0.01, ***P ≤ 0.001.
Fig. 3. Importance of IRE1α kinase in RNase activation in growth of MM cell lines in 3D versus 2D. (A) KMS-11 IRE1α knockout (KO) cells (Cl. 2.3) were transiently transfected with expression plasmids encoding wild-type IRE1α (WT RIRE1α), a “kinase-dead” D688N mutant of IRE1α (KD RIRE1α), or an “autophosphorylation-deficient” S724A, S726A, S729A triple mutant of IRE1α (PD RIRE1α). Cells were then incubated in the absence or presence of thapsigargin (Tg, 100 nM) for 3 h and analyzed either by IB for levels of the indicated proteins or by RT-qPCR for mRNA levels of XBP1s. (B) Chemical structures of compounds 18 and 16 (35) and KIRA6 (42). (C) A close-up view of the crystal structure of 18 in complex with the kinase-RNase portion of IRE1α. The protein is rendered in ribbons with key residues in the ligand-binding pocket shown as sticks. Water molecules near the ligand are shown in red spheres. Black dashed lines indicate hydrogen bonding interactions. (D) Comparison between the cocrystal structures of 18 (colored in wheat and orange versus 16 (PDB ID code 4U6R, colored cyan and blue) bound to IRE1α. The C-terminal end of the αC-helix displays significant conformational changes between the two structures. (E) KMS-11, OPM-2, and RPMI-8226 cells were seeded on standard tissue culture plates (2D) or ULA plates followed by centrifugation to form single spheroids (3D). After 96 h, cells were lysed and analyzed by IB for indicated proteins. (F–H) Cells were seeded either in the 2D or 3D setting, treated for 150 h with vehicle (DMSO) or compound 18 at the indicated concentrations, and analyzed for cell growth by cell confluence using an Incucyte instrument (F) or cell viability using CellTiter-Glo 3D (G and H). **P ≤ 0.01, ***P ≤ 0.001.CC BY-NC-ND · PubMed Central
Fig. 4. Small-molecule inhibition of IRE1α kinase attenuates s.c. and orthometastatic growth of human MM xenografts in mice. (A) KMS-11 cells stably transfected with doxycycline (Dox)-inducible shRNAs against IRE1α were inoculated s.c. into C.B-17 SCID mice and allowed to establish tumors of ∼200 mm3. Mice were then randomized into the following groups (n = 15 per group): vehicle, Dox in the drinking water (0.5 mg/kg), or compound 18 (30 mg/kg) intraperitoneally (IP) twice per day (BID). Tumor growth was monitored over 24 d. Individual tumor data are shown in SI Appendix, Fig. S4C. (B) OPM-2 cells stably transfected with Dox-inducible shRNAs against IRE1α were inoculated s.c. into C.B-17 SCID mice and allowed to establish tumors of ∼160 mm3. Mice were then randomized (n = 14 per group) treated as in A with either vehicle, Dox in the drinking water, or compound 18 IP once per day and monitored for tumor growth over 11 d. Individual tumor data are shown in SI Appendix, Fig. S4E. (C) RPMI-8226 cells expressing plasmids encoding mCherry and luciferase were injected i.v. via the tail vein of nonirradiated NOD/SCID/IL2rγ−/− mice and tumors were allowed to establish in the bone marrow over a period of 6 wk. Tumor burden was monitored by in-life imaging of luminescence. After 6 wk, mice were grouped out based on similar tumor burden, treated with vehicle (n = 3) or compound 18 (30 mg/kg IP, BID, n = 5) for 2 wk, and analyzed for tumor burden. One control mouse died during anesthesia and one treated mouse was killed due to weight loss. Luminescence images of representative mice are depicted on the left. The tumor burden of each mouse is shown as percent tumor growth on day 14 (at the end of 8 wk) compared with day 0 of treatment (Tx, at the end of 6 wk). **P ≤ 0.01, ***P ≤ 0.001.
Fig. 4. Small-molecule inhibition of IRE1α kinase attenuates s.c. and orthometastatic growth of human MM xenografts in mice. (A) KMS-11 cells stably transfected with doxycycline (Dox)-inducible shRNAs against IRE1α were inoculated s.c. into C.B-17 SCID mice and allowed to establish tumors of ∼200 mm3. Mice were then randomized into the following groups (n = 15 per group): vehicle, Dox in the drinking water (0.5 mg/kg), or compound 18 (30 mg/kg) intraperitoneally (IP) twice per day (BID). Tumor growth was monitored over 24 d. Individual tumor data are shown in SI Appendix, Fig. S4C. (B) OPM-2 cells stably transfected with Dox-inducible shRNAs against IRE1α were inoculated s.c. into C.B-17 SCID mice and allowed to establish tumors of ∼160 mm3. Mice were then randomized (n = 14 per group) treated as in A with either vehicle, Dox in the drinking water, or compound 18 IP once per day and monitored for tumor growth over 11 d. Individual tumor data are shown in SI Appendix, Fig. S4E. (C) RPMI-8226 cells expressing plasmids encoding mCherry and luciferase were injected i.v. via the tail vein of nonirradiated NOD/SCID/IL2rγ−/− mice and tumors were allowed to establish in the bone marrow over a period of 6 wk. Tumor burden was monitored by in-life imaging of luminescence. After 6 wk, mice were grouped out based on similar tumor burden, treated with vehicle (n = 3) or compound 18 (30 mg/kg IP, BID, n = 5) for 2 wk, and analyzed for tumor burden. One control mouse died during anesthesia and one treated mouse was killed due to weight loss. Luminescence images of representative mice are depicted on the left. The tumor burden of each mouse is shown as percent tumor growth on day 14 (at the end of 8 wk) compared with day 0 of treatment (Tx, at the end of 6 wk). **P ≤ 0.01, ***P ≤ 0.001.CC BY-NC-ND · PubMed Central
Fig. 5. Small-molecule inhibition of IRE1α kinase reduces viability of CD138+ MM cells in patient-derived samples without disrupting CD138− cells. (A–E) Bone marrow aspirates or peripheral blood obtained in the United States (A, C, and E) or European Union (B and D) from patients with newly diagnosed (NDx) or relapsed MM. Further information about age, gender, disease state, cytogenetics, and prior treatments is included in SI Appendix, Fig. S5A. Samples were cultured for 48 (A–C and E) or 72 h (D) with either vehicle (DMSO) or 10 μΜ compound (Cpd) 18 (A, B, and E), or two dose levels, 1 and 10 μΜ of compound (Cpd) 18 (C and D). Samples were then analyzed for viability by flow cytometry, with gating on CD138+ or CD138− cells. Nonmalignant bone marrow aspirates (n = 3) were similarly tested and are depicted for comparison (E). Data represent mean ± SD of triplicate determinations except where triplicates were not possible due to insufficient sample size. NS, not significant. *P < 0.05, ***P ≤ 0.001.
Fig. 5. Small-molecule inhibition of IRE1α kinase reduces viability of CD138+ MM cells in patient-derived samples without disrupting CD138− cells. (A–E) Bone marrow aspirates or peripheral blood obtained in the United States (A, C, and E) or European Union (B and D) from patients with newly diagnosed (NDx) or relapsed MM. Further information about age, gender, disease state, cytogenetics, and prior treatments is included in SI Appendix, Fig. S5A. Samples were cultured for 48 (A–C and E) or 72 h (D) with either vehicle (DMSO) or 10 μΜ compound (Cpd) 18 (A, B, and E), or two dose levels, 1 and 10 μΜ of compound (Cpd) 18 (C and D). Samples were then analyzed for viability by flow cytometry, with gating on CD138+ or CD138− cells. Nonmalignant bone marrow aspirates (n = 3) were similarly tested and are depicted for comparison (E). Data represent mean ± SD of triplicate determinations except where triplicates were not possible due to insufficient sample size. NS, not significant. *P < 0.05, ***P ≤ 0.001.CC BY-NC-ND · PubMed Central
Fig. 6. IRE1α kinase inhibition preserves survival and insulin secretion by pancreatic islet 3D microtissues and viability of primary hepatocytes. (A–C) Human pancreatic islets were isolated, dissociated, replated in microtiter wells (1,000 cells per drop), and allowed to form 3D microtissues over 7 d. Microtissues (n = 5 per treatment) were then (A) treated for 24 h with either vehicle control (DMSO) or tunicamycin (Tm, 5 μg/mL) in addition to either vehicle (DMSO) or compound 18, lysed, and then analyzed for XBP1s mRNA levels by RT-qPCR (%XBP1s mRNA is the ratio of XBP1s mRNA/(XBP1s mRNA+XBP1u mRNA); or (B and C) incubated for 7 d in the presence of either vehicle (DMSO) or compound 18 and then (B) analyzed for cell viability by CellTiter-Glo; or (C) challenged with glucose (16.7 mM) for 1 h and analyzed for insulin secretion by ELISA. (D and E) Human primary hepatocytes were treated for 8 h with either control or Tm in addition to either vehicle or compound 18 and analyzed for XBP1s levels as above by RT-qPCR (D). Alternatively, hepatocytes were cultured for 48 h in the presence of vehicle (DMSO) or compound 18 and analyzed for cell viability by CellTiter-Glo (E).
Fig. 6. IRE1α kinase inhibition preserves survival and insulin secretion by pancreatic islet 3D microtissues and viability of primary hepatocytes. (A–C) Human pancreatic islets were isolated, dissociated, replated in microtiter wells (1,000 cells per drop), and allowed to form 3D microtissues over 7 d. Microtissues (n = 5 per treatment) were then (A) treated for 24 h with either vehicle control (DMSO) or tunicamycin (Tm, 5 μg/mL) in addition to either vehicle (DMSO) or compound 18, lysed, and then analyzed for XBP1s mRNA levels by RT-qPCR (%XBP1s mRNA is the ratio of XBP1s mRNA/(XBP1s mRNA+XBP1u mRNA); or (B and C) incubated for 7 d in the presence of either vehicle (DMSO) or compound 18 and then (B) analyzed for cell viability by CellTiter-Glo; or (C) challenged with glucose (16.7 mM) for 1 h and analyzed for insulin secretion by ELISA. (D and E) Human primary hepatocytes were treated for 8 h with either control or Tm in addition to either vehicle or compound 18 and analyzed for XBP1s levels as above by RT-qPCR (D). Alternatively, hepatocytes were cultured for 48 h in the presence of vehicle (DMSO) or compound 18 and analyzed for cell viability by CellTiter-Glo (E).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 115

Metadata

Authors
Harnoss, J. M., Le Thomas, A., Shemorry, A., Marsters, S. A., Lawrence, D. A., Lu, M., Chen, Y.-C. A., Qing, J., Totpal, K., Kan, D., Segal, E., Merchant, M., Reichelt, M., Ackerly Wallweber, H., Wang, W., Clark, K., Kaufman, S., Beresini, M. H., Laing, S. T., Sandoval, W., Lorenzo, M., Wu, J., Ly, J., De Bruyn, T., Heidersbach, A., Haley, B., Gogineni, A., Weimer, R. M., Lee, D., Braun, M.-G., Rudolph, J., VanWyngarden, M. J., Sherbenou, D. W., Gomez-Bougie, P., Amiot, M., Acosta-Alvear, D., Walter, P., & Ashkenazi, A.
Affiliations
  • Genentech (US)
  • Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080;
  • Translational Oncology, Genentech, Inc., South San Francisco, CA 94080;
  • Structural Biology, Genentech, Inc., South San Francisco, CA 94080;
  • Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA 94080;
  • University of Colorado Cancer Center (US)
  • Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, CNRS, Université d’Angers, Université de Nantes, BP 70721 Nantes, France;
  • Centre National de la Recherche Scientifique (FR)
  • Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143;
  • Howard Hughes Medical Institute (US)
Corresponding author
Ashkenazi, Avi
Venue
Proceedings of the National Academy of Sciences
Published
2019-08
Volume
116
Issue
33
Pages
16420-16429
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2964798481
Cited by
109
References
52
Citations by year
2026: 8 · 2025: 18 · 2024: 8 · 2023: 15 · 2022: 13 · 2021: 22 · 2020: 21 · 2019: 3
FWCI
7.95
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • Howard Hughes Medical Institute (HHMI Collaborative Innovation Award, HHMI Investigator Award)
  • Cancer Research Institute (Irvington Postdoctoral Fellowship)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
Keywords
multiple myeloma, IRE1α, endoplasmic reticulum stress, XBP1, unfolded protein response, plasma cells, small-molecule kinase inhibitors, therapeutic target
MeSH terms
Bortezomib, X-Box Binding Protein 1, Lenalidomide, Aged, Animals, Endoribonucleases, Female, Humans, Male, Middle Aged, Multiple Myeloma, Signal Transduction, Gene Expression Regulation, Neoplastic, Protein Serine-Threonine Kinases, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Mice, Unfolded Protein Response, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disruption of IRE1α through its kinase domain attenuates multiple myeloma. https://app.cochat.ai/papers/10.1073/pnas.1906999116
The paper
Harnoss, J. M., Le Thomas, A., Shemorry, A., Marsters, S. A., Lawrence, D. A., Lu, M., Chen, Y.-C. A., Qing, J., Totpal, K., Kan, D., Segal, E., Merchant, M., Reichelt, M., Ackerly Wallweber, H., Wang, W., Clark, K., Kaufman, S., Beresini, M. H., Laing, S. T., . . . Ashkenazi, A. (2019). Disruption of IRE1α through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1906999116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.